The FDA Does Something Right
I know, the headline makes you want to read it twice. Can the U.S. FDA really do something right, and that is in the interest of the public?
The FDA has approved the first generic versions of AZT, the grand old daddy of AIDs medications. It should be clarified that this is not the first version of the drug, but rather the first version that will be made available in the U.S. Glaxo’s patent has finally run its term, after 18 years, and like it or not, the FDA must allow the generics to move in. I should add that generic versions are already being manufactured in countries like India and China, where they can’t afford to pay the cost of patented medicine.
AZT currently costs about $2,200 for a one-year supply, far more than the average person in a developing nation could ever afford to pay. When AZT first came on the market in 1987, the price tag was about $10,000. So while the cost has declined dramatically, it’s still pricey, especially for people who don’t earn that much in a year. Generic versions of the drug cost as little as $105 for a one-year supply, and U.S.-made generics could be even cheaper than that. Now that will be a boon to saving costs in healthcare, wouldn’t it.
There have some fierce battles over patent vs. generic when it comes to AIDS drugs. Developing nations, home to about 80% of all AIDS cases, simply cannot afford to pay for patented drugs, even with discounts offered by the manufacturer. Thus, breaking patents and making generics was seen as a necessity by many developing nations, and I can’t blame them. I can understand a company wanted exclusivity after they put a drug on the market, but in the case of AIDS, the high prices simply meant that the majority of AIDS patients were just going to die untreated.

